TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06208202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive and use flavored e-cigarettes (EC) as directed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive and use flavored e-cigarettes (EC) as directed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive and use flavored e-cigarettes (EC) as directed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive and use flavored e-cigarettes (EC) as directed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo biosample sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo biosample sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo biosample sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo biosample sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05840211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally
Study: NCT06152237

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TSHA-102
Description: TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TSHA-102
Description: TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
Study: NCT05209464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-Tai Chi
Description: Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
Study: NCT06533956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week gait training program combined with simultaneous blood flow restriction (BFR).
Description: The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
Study: NCT05342623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difelikefalin 1 mg Oral Tablet
Description: Difelikefalin 1 mg medication taken orally 1 time/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken orally 1 time/day
Study: NCT04793490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine ganglion block
Description: Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: patients will receive paracetamol 1 g thrice daily intravenously
Study: NCT05582408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measures of Standard Noise Reduction NR1
Description: Each participant will be fitted with the Standard Noise Reduction (NR1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measures of Noise Reduction Principle NR2
Description: Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measure of Noise Reduction Principle NR3
Description: Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
Study: NCT04957537

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: semantic therapy and semantic re-education
Description: Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: semantic therapy and semantic re-education
Description: Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes).
Study: NCT06513351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel PPH Risk Prediction Model - Comparator Arm B
Description: Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
Study: NCT04987879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
Study: NCT06292156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta treatment group
Description: The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha active control group
Description: The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control group
Description: Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).
Study: NCT06491511

Intervention type: PROCEDURE
Intervention: Transcutaneous, repetitive phrenic nerve electrical stimulation
Description: Phrenic nerve electrical stimulation with different stimulation intensity and frequency
Study: NCT05597254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic with niacin and berry extract
Description: 1 capsule daily of probiotic with niacin supplementation for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic without niacin and berry extract
Description: 1 capsule daily of probiotic without niacin supplementation for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily of placebo supplementation for 8 weeks
Study: NCT04665635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectosigmoid resection
Description: Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectosigmoid resection
Description: Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
Study: NCT05066230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal injection
Study: NCT05384626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-655
Description: Oral Tablet of NVL-655
Study: NCT06551974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help plus IPT
Description: The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help
Description: The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
Study: NCT06496048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
Study: NCT04934423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Current Transcranial Stimulation - tDCS
Description: Active intervention

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Direct Current Transcranial Stimulation - Sham intervention
Study: NCT04481737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-delivered and Technology Support Integrated Illness Management and Recovery
Description: PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
Study: NCT04852536

Intervention type: DEVICE
Intervention: Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS
Description: 5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.
Study: NCT05586152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study: NCT05064696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-stick gauze dressing
Description: Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
Study: NCT06166446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subtractive technique
Description: The milled denture teeth are then bonded into the milled recesses using a special PMMA bonding system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: additive technique
Description: The denture teeth were printed as one unit using the same method with tooth resin (DENTCA Denture Tooth, Shade A2).
Study: NCT05064696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO dressing
Description: Group 2 (Treatment group): surgical site will be dressed with PICO dressing
Study: NCT06467422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tTIS on dACC, theta frequency (5 Hz)
Description: Device: Transcranial electric stimulation device~The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.006 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 6 Hz can be generated in the target area. The experimental group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tTIS on dACC, High frequency
Description: The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The sham group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.
Study: NCT06205342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Autologous bone marrow derived MSCs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Control
Study: NCT05666453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIV-GAMMA SN Inj.
Description: LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: None of investigational drugs are administered to patients.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: None of investigational drugs are administered to patients.
Study: NCT04991467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program and Valera Application with care manager functionality
Description: Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program and Valera Application with care manager functionality
Description: Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valera Application with care manager functionality
Description: Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valera Application with care manager functionality
Description: Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program
Description: Participant will take part in 12 week CARE program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program
Description: Participant will take part in 12 week CARE program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program
Description: Participant will take part in 12 week CARE program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valera Application
Description: Participant will receive the Valera health application which will provide parent education materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Program and Valera Application
Description: Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
Study: NCT06448754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Participants will receive volrustomig via intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Participants will receive volrustomig via intravenous (IV) infusion.